Cilansetron: a novel, high-affinity 5-HT₃ receptor antagonist for irritable bowel syndrome with diarrhea predominance

ISSN： 1475-0708

Source： Therapy, Vol.2, Iss.4, 2005-07, pp. : 559-567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes

By Bleser Scott

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome

By Harris Lucinda A Chang Lin

Women's Health, Vol. 3, Iss. 1, 2007-01 ,pp. : 15-27

Future Medicine

Access to resources Recommend Favorite

Postinfectious irritable bowel syndrome after travelers' diarrhea – a cohort study

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 8, 2015-08 ,pp. : 1147-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐HT3 receptor antagonist

EUROPEAN JOURNAL OF CANCER CARE (ELECTRONIC), Vol. 24, Iss. 3, 2015-05 ,pp. : 436-443

John Wiley & Sons Inc

Access to resources Recommend Favorite

Irritable bowel syndrome and somatization

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 5, 2015-05 ,pp. : 740-740

John Wiley & Sons Inc

Access to resources Recommend Favorite